Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.
Cancer Med. 2018 Jun;7(6):2256-2268. doi: 10.1002/cam4.1422. Epub 2018 Apr 19.
Cancer Med. 2018.
PMID: 29673108
Free PMC article.
Clinical Trial.
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.
Jakobsen Falk I, Lund J, Gréen H, Gruber A, Alici E, Lauri B, Blimark C, Mellqvist UH, Swedin A, Forsberg K, Carlsson C, Hardling M, Ahlberg L, Lotfi K, Nahi H.
Jakobsen Falk I, et al. Among authors: hardling m.
Cancer Chemother Pharmacol. 2018 Jan;81(1):183-193. doi: 10.1007/s00280-017-3481-8. Epub 2017 Nov 25.
Cancer Chemother Pharmacol. 2018.
PMID: 29177954
Free PMC article.
Clinical Trial.
Item in Clipboard
Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial.
Johansson JE, Bratel J, Hardling M, Heikki L, Mellqvist UH, Hasséus B.
Johansson JE, et al. Among authors: hardling m.
Bone Marrow Transplant. 2019 Sep;54(9):1482-1488. doi: 10.1038/s41409-019-0468-6. Epub 2019 Feb 4.
Bone Marrow Transplant. 2019.
PMID: 30718802
Clinical Trial.
Item in Clipboard
An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients.
Nahi H, Hägglund H, Ahlgren T, Bernell P, Hardling M, Karlsson K, Lazarevic VLj, Linderholm M, Smedmyr B, Aström M, Hallböök H.
Nahi H, et al. Among authors: hardling m.
Haematologica. 2008 Nov;93(11):1734-8. doi: 10.3324/haematol.13227. Epub 2008 Aug 25.
Haematologica. 2008.
PMID: 18728022
Free article.
Item in Clipboard
Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
Wei Y, et al. Among authors: hardling m.
Ann Hematol. 2006 Dec;85(12):841-7. doi: 10.1007/s00277-006-0171-8. Epub 2006 Sep 28.
Ann Hematol. 2006.
PMID: 17006667
Clinical Trial.
Item in Clipboard
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.
Hardling M, et al.
Med Oncol. 2004;21(4):349-58. doi: 10.1385/MO:21:4:349.
Med Oncol. 2004.
PMID: 15579919
Item in Clipboard
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group.
Attal M, et al.
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.
Lancet. 2019.
PMID: 31735560
Clinical Trial.
Item in Clipboard
Cite
Cite